Recommendations developed for management of hidradenitis suppurativa

by Elana Gotkine

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

reputable news agency

proofread

The GIST Add to Preferred Sources

Evidence-based recommendations are presented for the management of hidradenitis suppurativa (HS) in guidelines of care issued by the American Academy of Dermatology and the Hidradenitis Suppurativa Foundation and published online Oct. 20 in the Journal of the American Academy of Dermatology.

Haley B. Naik, M.D., from the University of California in San Francisco, and colleagues conducted a systematic review to provide evidence-based recommendations for the management of HS.

The authors presented 37 evidence-based recommendations. Adalimumab, bimekizumab, infliximab, secukinumab and routine pain assessment were strongly recommended. Conditional recommendations included use of topical therapies (clindamycin, resorcinol and ruxolitinib), as well as systemic antibiotics (oral doxycycline, tetracycline, clindamycin with rifampin and intravenous ertapenem). In addition, there were conditional recommendations for hormone therapy with spironolactone, short-term systemic corticosteroids and upadacitinib. Specific procedural interventions, tobacco cessation, supportive pain management, and zinc supplementation and vitamin D repletion were also conditionally recommended.

"These guidelines establish an evidence-based standard of care for HS, giving patients, dermatologists and payers a shared roadmap for what high-quality HS care looks like," Naik said in a statement. "Every person living with HS deserves care that meets this standard."

Publication details

Haley B. Naik et al., Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa, Journal of the American Academy of Dermatology (2026). DOI: 10.1016/j.jaad.2026.08.125

Journal information: Journal of the American Academy of Dermatology

Key medical concepts

Hidradenitis SuppurativaInfliximabAdalimumabsecukinumabbimekizumab

Clinical categories

DermatologyClinical pharmacologyCommon illnesses & Prevention Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

© 2026 HealthDay. All rights reserved.

Citation: Recommendations developed for management of hidradenitis suppurativa (2026, October 28) retrieved 29 October 2026 from https://medicalxpress.com/news/2026-10-hidradenitis-suppurativa.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.